Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as a tablet for oral use. It is used to treat chronic lymphocytic leukemia, Hodgkin's lymphoma and other lymphoid malignancies.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran (chlorambucil) is employed in the management of lymphoid malignancies.

Chronic lymphocytic leukemia: helps achieve disease control and prolong remission. Hodgkin's lymphoma: contributes to tumor reduction and symptom relief. Other lymphoid malignancies: provides therapeutic benefit as part of combination regimens.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Loss of appetite - Fatigue or weakness - Mild leukopenia - Alopecia (hair loss) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe bone‑marrow suppression leading to pancytopenia - Life‑threatening infections due to immunosuppression - Secondary malignancies such as acute leukemia - Hepatic toxicity with elevated liver enzymes - Severe allergic reactions including anaphylaxis - Pulmonary fibrosis or interstitial lung disease

Key safety considerations should be observed before and during therapy. - Pregnancy: contraindicated (Category D) due to fetal risk. - Breastfeeding: not recommended; drug may be excreted in milk. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution and consider dose modification. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Potential drug interactions may affect efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: additive bone‑marrow toxicity. - High‑dose radiation therapy: increased risk of severe tissue damage. - Live vaccines: risk of uncontrolled infection. - Strong CYP2D6 inhibitors: may raise chlorambucil plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase gastrointestinal irritation. - Azathioprine: additive myelosuppressive effect. - Allopurinol: can enhance chlorambucil toxicity. - ACE inhibitors: monitor renal function when combined.